Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A fully validated simple new method for environmental monitoring by surface sampling for cytotoxics.

Rossignol E, Amiand MB, Sorrieul J, Bard JM, Bobin-Dubigeon C.

J Pharmacol Toxicol Methods. 2020 Jan - Feb;101:106652. doi: 10.1016/j.vascn.2019.106652. Epub 2019 Nov 15.

PMID:
31734280
2.

Effect of milk fat on LDL cholesterol and other cardiovascular risk markers in healthy humans: the INNOVALAIT project.

Bard JM, Drouet L, Lairon D, Cazaubiel M, Marmonier C, Ninio E, Bal Dit Sollier C, Martin JC, Boyer C, Bobin-Dubigeon C; INNOVALAIT Study group.

Eur J Clin Nutr. 2020 Feb;74(2):285-296. doi: 10.1038/s41430-019-0528-4. Epub 2019 Nov 11.

PMID:
31712768
3.

New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.

Bobin-Dubigeon C, Campone M, Rossignol E, Salaun E, Amiand MB, Bard JM.

Future Sci OA. 2019 Mar 22;5(5):FSO374. doi: 10.2144/fsoa-2018-0113. eCollection 2019 Jun.

4.

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

5.

Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells.

Luu TH, Bard JM, Carbonnelle D, Chaillou C, Huvelin JM, Bobin-Dubigeon C, Nazih H.

Cell Oncol (Dordr). 2018 Feb;41(1):13-24. doi: 10.1007/s13402-017-0353-5. Epub 2017 Oct 9.

PMID:
28993998
6.

Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.

Bobin-Dubigeon C, Chauvin A, Brillaud-Meflah V, Boiffard F, Joalland MP, Bard JM.

Anticancer Res. 2017 Oct;37(10):5495-5498.

PMID:
28982861
7.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

8.

Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer.

Luu TH, Michel C, Bard JM, Dravet F, Nazih H, Bobin-Dubigeon C.

Nutr Cancer. 2017 Feb-Mar;69(2):267-275. doi: 10.1080/01635581.2017.1263750. Epub 2017 Jan 17.

PMID:
28094541
9.

Leptin and adiponectin as new markers of undernutrition in cancer.

Bobin-Dubigeon C, Lefrançois A, Vansteene D, Dupé M, Joalland MP, Bard JM.

Clin Biochem. 2017 Jun;50(9):525-528. doi: 10.1016/j.clinbiochem.2017.01.001. Epub 2017 Jan 6.

PMID:
28069486
10.

Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.

Bobin-Dubigeon C, Lefrançois A, Classe JM, Joalland MP, Bard JM.

Clin Biochem. 2015 Nov;48(16-17):1181-3. doi: 10.1016/j.clinbiochem.2015.07.020. Epub 2015 Jul 17.

PMID:
26188919
11.

Short communication: Paraoxonase 1 (PON1) in French HIV-infected patients under antiretroviral therapy: relationship with the metabolic syndrome and inflammation.

Bobin-Dubigeon C, Biron C, Volteau C, Piroth L, Biron A, Perré P, Leport C, Prazuck T, Sébille-Rivain V, Raffi F, Bard JM.

AIDS Res Hum Retroviruses. 2013 Dec;29(12):1571-4. doi: 10.1089/AID.2013.0010. Epub 2013 Aug 2.

PMID:
23837895
12.

A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination.

Bobin-Dubigeon C, Amiand M, Percheron C, Audeval C, Rochard S, Leynia P, Bard JM.

J Anal Toxicol. 2013 Sep;37(7):433-9. doi: 10.1093/jat/bkt045. Epub 2013 Jul 4.

PMID:
23828102
13.

Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.

Biron A, Bobin-Dubigeon C, Volteau C, Piroth L, Perré P, Leport C, Prazuck T, Jovelin T, Billard M, Sébille V, Bard JM, Raffi F, Biron C.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1672-8. doi: 10.1089/AID.2012.0048. Epub 2012 Jul 25.

PMID:
22731114
14.

Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence.

Bobin-Dubigeon C, Jaffré I, Joalland MP, Classe JM, Campone M, Hervé M, Bard JM.

Clin Biochem. 2012 Nov;45(16-17):1503-5. doi: 10.1016/j.clinbiochem.2012.05.021. Epub 2012 May 29.

PMID:
22659076
15.

A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.

Bobin-Dubigeon C, Heurgue-Berlot A, Bouché O, Amiand MB, Le Guellec C, Bard JM.

Ther Drug Monit. 2011 Dec;33(6):705-10. doi: 10.1097/FTD.0b013e3182357891.

PMID:
22105587
16.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
17.

Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma.

Bobin-Dubigeon C, Amiand MB, Herrenknecht C, Bard JM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 15;877(24):2451-6. doi: 10.1016/j.jchromb.2009.06.020. Epub 2009 Jun 21.

PMID:
19560408
18.

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.

Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28.

19.

[PPAR alpha-L162V, frequency and relationship with type 2 diabetes among black Senegalese people].

Lopez-Sall P, Bard JM, Nazih H, Cissé A, Bobin-Dubigeon C, Sall ND.

Ann Biol Clin (Paris). 2008 Jul-Aug;66(4):475-7. doi: 10.1684/abc.2008.0253. French.

20.

Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis.

Bobin-Dubigeon C, Collin X, Grimaud N, Robert JM, Le Baut G, Petit JY.

Eur J Pharmacol. 2001 Nov 9;431(1):103-10.

PMID:
11716848
21.

New anti-inflammatory N-pyridinyl(alkyl)phthalimides acting as tumour necrosis factor-alpha production inhibitors.

Collin X, Robert J, Wielgosz G, Le Baut G, Bobin-Dubigeon C, Grimaud N, Petit J.

Eur J Med Chem. 2001 Jul-Aug;36(7-8):639-49.

PMID:
11600233
22.

Synthesis of N-pyridinyl(methyl)-1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamides and analogues and their anti-inflammatory activity in mice and rats.

Collin X, Robert JM, Duflos M, Wielgosz G, Le Baut G, Bobin-Dubigeon C, Grimaud N, Lang F, Petit JY.

J Pharm Pharmacol. 2001 Mar;53(3):417-23. Erratum in: J Pharm Pharmacol 2001 Dec;53(12):1729. Robin-Dubigeon C [corrected to Bobin-Dubigeon C].

PMID:
11291760
23.

Secreted and intracellular phospholipases A2 inhibition by 1-decyl 2-octyl-glycerophosphocholine in rat peritoneal macrophages.

Boucrot P, Bobin-Dubigeon C, Elkihel L, Letourneux Y, Jugé M, Gandemer G, Petit JY.

Fundam Clin Pharmacol. 1998;12(4):433-41.

PMID:
9711466

Supplemental Content

Loading ...
Support Center